Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...
Truist raised the firm’s price target on Equity Residential (EQR) to $78 from $76 and keeps a Buy rating on the shares. The firm updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results